Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2016-06-02 Capital/Financing Update
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive share upgraded to OTC Markets Group – OTCQX Best Market in the US
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that NeuroVive Pharmaceutical AB's shares have been upgraded to trade on the OTCQX Best Market in the US. This announcement concerns the company's listing status and accessibility to US investors, which is a corporate action related to capital structure or market presence. It is not a standard financial report (10-K, IR, ER, MRQ), an AGM material, a management change, or a dividend notice. Since it is a specific corporate announcement that doesn't fit the primary financial reporting codes, it falls best under a general regulatory/corporate announcement category. Given the options, 'Capital/Financing Update' (CAP) is plausible as it relates to trading venue and investor access, but 'Regulatory Filings' (RNS) serves as a strong fallback for general corporate news releases that don't fit the highly specific categories. However, because the core subject is the upgrade of the trading venue, which directly impacts capital market access and investor relations, CAP is a slightly better fit than the general RNS, although RNS is also acceptable for non-standard news releases. I will classify it as CAP because the upgrade directly affects the capital market structure for US investors. The document is a press release, not a formal regulatory filing like a 10-K or a report itself, so RPA/RNS are alternatives, but CAP captures the essence of the news better than RNS.
2016-06-02 English
Major Shareholding Notification 2016
Major Shareholding Notification Classification · 1% confidence The document explicitly details changes in shareholding percentages and quantities for a specific instrument, including 'Before the transaction' and 'After the transaction' figures, and mentions a 'Reason for major shareholding notification'. This structure directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is a formal notification of ownership change, not a general announcement of a report (RPA/RNS) or a full annual/interim report.
2016-06-01 English
NeuroVive Pharmaceutical AB (publ) - amendment number of shares and votes
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated May 31, 2016, announcing an amendment to the number of shares and votes following a new share issue resolved by the Board and approved by the EGM. The core subject is the increase in the total number of shares (49,458,645) due to a capital action. This directly relates to changes in the company's capital structure or share count. Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate classification, as it explicitly covers announcements regarding new share issues or capital changes. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a financing update (CAP) which usually implies fundraising activities rather than the mechanical result of an already completed issue.
2016-05-31 English
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and is dated May 31, 2016. The core content announces a change in the number of shares and votes following a recent rights issue ('nyemission') approved by the board and shareholders. This directly relates to a change in the company's capital structure (share count increase). Based on the definitions, the category 'Share Issue/Capital Change' (SHA) is the most appropriate fit, as it covers announcements regarding new share issues or capital structure changes. It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV). The document is a specific announcement about a capital event.
2016-05-31 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport 2016' (Interim Report 2016) and covers the period from 2016-01-01 to 2016-03-31. It contains comprehensive financial data, including income statements, cash flow, balance sheet information, and management commentary on business operations and risks. It is a full quarterly report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). Q1 2016
2016-05-31 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report 2016' and covers the period from 1 January 2016 to 31 March 2016. It contains detailed financial statements, including revenue, operating loss, cash flow, and balance sheet data, as well as management commentary on business operations and strategy. It is a comprehensive quarterly report, not an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). Q1 2016
2016-05-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.